Reported Sunday, Molecular Partners Nominates MP0632 As First Logic-Gated Switch-DARPin T Cell Engager Candidate For MSLN/EpCAM-Expressing Solid Tumors With Favorable Therapeutic Window At AACR 2026
MP0632 nominated as first logic-gated Switch-DARPin T cell engager candidate for the treatment of MSLN/EpCAM expressing solid tumors, with preclinical data indicating favorable therapeutic window
MP0712, Radio-DARPin candidate in on-going US Phase 1/2a trial, leverages high affinity to DLL3, half-life extension and DLL3 internalization for high tumor accumulation
Login to comment